The difference between that patient and someone simply seeking a sleep aid is the difference between informed participation in something experimental and an inappropriate clinical promise
A 2019 network meta-analysis of 233 trials (n = 147,710) reported elevated risks of dizziness (odds ratios [ORs] 1.92, 1.57, 1.40) and headache (ORs 1.34, 1.41, 1.18) with GLP-1 RAs versus insulin, thiazolidinediones, and placebo 40
Important contraindications exist
Targets neurotransmitter and circadian rhythm pathways
Key Target Audience Market Players Investors End-users Government Authorities Consulting and Research Firm Venture capitalists Value-Added Resellers (VARs) Recent Development In April 2025, ProRx Pharma launched four new injectables in its health and wellness product line: Sermorelin, NAD+, Glutathione, and MIC/B6/B12
Elevated levels could reflect a protective response to injury rather than a causal factor